IRE1alpha inhibitors (OptiKira)

N/A

Report date: 2025/03/20 15:05:46
NME

Base Information

Drug NameIRE1alpha inhibitors (OptiKira)
Drug Alias NameIRE1alpha inhibitors (University of California San Franciso/University of Washington)kinase-inhibiting RNase attenuators (OptiKira)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase/endoribonuclease IRE1 inhibitors
TargetsSerine/threonine-protein kinase/endoribonuclease IRE1
Therapy Area/IndicationsDiabetes MellitusRetinitis PigmentosaAmyotrophic Lateral Sclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOptiKira
China Registration ClassN/A

Develop Information

Active CompaniesOptiKira
Inactive CompaniesN/A
Active IndicationsDiabetes MellitusRetinitis PigmentosaAmyotrophic Lateral Sclerosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A